ACEA Biosciences Reports Positive Phase I Trial of BTK Inhibitor

ACEA Biosciences, a San Diego-Hangzhou company, has completed a successful Phase I trial of a novel irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor. ACEA makes and markets innovative tools for cell-based assays that examine the effects of drugs on target cells. Using its products and an expertise in covalent tyrosine kinase inhibitors, ACEA has multiple clinical stage programs in the US and China. Its BTK inhibitor, AC0058, is aimed at B cell-related autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. In the Phase I trial, healthy volunteers were given ascending doses of AC0058 without reaching the maximum tolerated dose. More details....

Share this with colleagues: